Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abiraterone, acute, amplification, antigen, aspartate, baseline, biology, biosimilar, bona, circulating, coalition, cohort, concomitant, concurrent, confirmed, costliest, cutoff, deep, denial, disabled, DNA, elevated, elevation, embedded, enzalutamide, epinephrine, evidence, fide, harbor, index, India, Inline, insulin, interaction, Interactive, liver, meant, mg, Page, PBM, pharmacy, PSA, pump, radiographic, RECIST, remotely, renal, reopened, rescind, resistance, resistant, retreated, reversed, ROS, rosuvastatin, screening, sequester, short, shrinkage, shut, Solid, splice, substrate, threshold, transaminase, transport, transporter, vitro, wildtype
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view